RxDoctor Payments Data

Tom Yan, MD

Pulmonary Disease · Silverdale, WANPI 1962515742

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (47.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 98.7% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $5,251, more than ten times the $68 reported in 2019.

$8,486in general payments, 2019–2025

Across 20 payments — averaging $424.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • GSK$68
  • Insmed, Inc.$42

What the payments were for

  • Travel & lodging$3,70444%
  • Food & beverage$7819%
  • Education$4,00047%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical17$8,375
GSK1$68
Insmed, Inc.2$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,486 in reported general payments places this provider in the 85th percentile of 275 pulmonary disease providers in Washington.

See all pulmonary disease providers in Washington

Medicare billing

Part B allowed, 2024
$206,300
Medicare patients
665
Services billed
2,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr381$215,313
Trelegy ElliptaFluticasone/Umeclidin/Vilanter206$169,527
TezspireTezepelumab-Ekko22$99,483
Stiolto RespimatTiotropium Br/Olodaterol Hcl117$84,784
Spiriva RespimatTiotropium Bromide95$67,168
Dupixent PenDupilumab14$58,699
Breo ElliptaFluticasone/Vilanterol48$26,285
Combivent RespimatIpratropium/Albuterol Sulfate14$20,083
SymbicortBudesonide/Formoterol Fumarate59$17,045
Incruse ElliptaUmeclidinium Bromide23$13,440
DuleraMometasone/Formoterol33$13,009
Arnuity ElliptaFluticasone Furoate41$12,469
Advair HfaFluticasone Propion/Salmeterol13$6,470
Albuterol Sulfate HfaAlbuterol Sulfate279$6,257
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$4,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$68$437,034699 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 pulmonary disease providers in Washington.

Other pulmonary disease in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →